Moderna and Merck's mRNA Cancer Vaccine: A New Era in Oncology?
Moderna and Merck's Phase 3 trial results could transform the mRNA oncology landscape and boost their market positions.
Nuvation Bio's Stock Surge: Analyzing the FDA's Impact on Future Growth
Nuvation Bio’s stock saw a significant rise following the FDA’s label update for IBTROZI, indicating potential growth in the pharmaceutical market.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
S&P Global's Acquisition of OpenZeppelin: Implications for Digital Asset Risk Assessment
S&P Global's acquisition of OpenZeppelin marks a pivotal shift in digital asset risk assessment. What does this mean for…
DataMeds AI (MEDS) Experiences Explosive Growth: What It Means for AI in Oncology
DataMeds AI has seen a dramatic surge in stock price following its acquisition of Helomics, raising questions for trader…
Moderna and Merck's mRNA Cancer Vaccine: A Game Changer for Oncology?
The Phase 3 INTerpath-001 trial results could reshape the landscape of oncology and investor sentiment in the pharmaceut…
TerrAscend Strengthens Market Position with Aunt Mary's Acquisition
TerrAscend enhances its New Jersey presence with the acquisition of Aunt Mary's, expanding its retail footprint and stra…
Fed Decision Day: What Higher Treasury Yields Mean for US Markets
Analyzing the impact of rising Treasury yields and Fed decisions on various sectors and market indices.
Merck and Moderna's mRNA-4157: A Breakthrough in Personalized Cancer Vaccines
Merck and Moderna's Phase 3 trial results could reshape the oncology landscape with personalized mRNA cancer vaccines.
MBody AI's Strategic Shift: $10 Million Offering Fuels Embodied AI Ambitions
MBody AI's recent name change and $10 million offering signal a bold step into the thriving embodied AI market.
Merck and Moderna's Cancer Vaccine: A Game Changer for mRNA Technology?
The Phase 3 INTerpath-001 trial success positions Merck and Moderna at the forefront of mRNA cancer vaccines, potentiall…
GFL Environmental's Take-Private Consideration: Implications for Investors on TSX and NYSE
GFL Environmental's move to explore a take-private transaction raises questions for investors on the TSX and NYSE.